Aulis Capital

Aulis Capital is a global investment firm specializing in healthcare, partnering with early- and growth-stage companies to accelerate innovations that improve patient care and advance medical technology. The firm leverages over 20 years of expertise, a unique global network, and scientific, analytical, and investment acumen to empower visionary entrepreneurs developing pioneering solutions. Its mission centers on building a healthier and more equitable world through transformative healthcare innovations while delivering superior returns by aligning capital with ideas that drive human health progress. While specific founding details remain undisclosed in available sources, Aulis Capital emphasizes cross-border collaboration, as noted by industry figure Nisa Leung, reflecting its strategy rooted in international partnerships across key innovation hubs. The firm operates funds such as Aulis Capital Fund I, LP, which filed a Form D notice in December 2025, indicating active fundraising and deployment in the sector. No public information details the founders' backgrounds or the exact inception year, suggesting a relatively recent or low-profile establishment focused on operational impact over historical narrative. Aulis Capital maintains a targeted portfolio in healthcare, though specific portfolio companies and notable investments are not publicly detailed in current records. The firm's approach prioritizes high-potential early- and growth-stage opportunities in medical technology and patient care advancements, positioning it as a bridge for cross-border deals in a competitive landscape. The team at Aulis Capital draws on deep scientific and investment expertise, supported by offices in major global centers including Palo Alto or Menlo Park, Boston, Shanghai, Beijing, and Hong Kong. This multinational presence enables robust support for entrepreneurs shaping healthcare's future, with a commitment to staying at the industry's forefront through dedicated entrepreneur engagement.